Clinical Trials Logo

Fallopian Tube Adenocarcinoma clinical trials

View clinical trials related to Fallopian Tube Adenocarcinoma.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT04630769 Completed - Ovarian Cancer Clinical Trials

FT516 and IL2 With Enoblituzumab for Ovarian Cancer

Start date: April 2, 2021
Phase: Phase 1
Study type: Interventional

This is a single center Phase I clinical trial of FT516 administered intraperitoneally (IP) once a week for 3 consecutive weeks for the treatment of recurrent gynecologic cancers. As this is an early 1st in human study and the 1st intraperitoneal infusion of FT516, the safety of FT516 is confirmed prior to adding enoblituzumab as an intravenous infusion approximately 1 week prior to the 1st dose of FT516 and every 3 weeks beginning on Day 22 (1 week after the last dose of FT516). Each dose of FT516 is followed directly by an IP infusion of interleukin-2 (IL-2) to facilitate natural killer (NK) cell survival. A short course of outpatient lymphodepletion chemotherapy is given prior to the 1st dose of FT516.

NCT ID: NCT03593681 Completed - Ovarian Cancer Clinical Trials

Compare Fallopian Tube Cells Collected by Cytuity With Removed Ovarian/Tubal Tissue to Determine Presence of Malignancy

nCYT
Start date: August 27, 2018
Phase:
Study type: Observational

Prospective, multi-center, non-randomized study to assess the ability of the Cytuity device to collect cell samples from the fallopian tube that can be evaluated for the presence or absence of malignancy.

NCT ID: NCT02217956 Completed - Clinical trials for Primary Peritoneal Carcinoma

Dose Escalation of Cisplatin Hyperthermic Intraperitoneal Chemotherapy After Surgery in Patients With Unresectable Stage IIIC Ovarian, Tube or Peritoneal Primary Adenocarcinoma

CHIPASTIN
Start date: June 2011
Phase: Phase 1
Study type: Interventional

HCIP has shown efficacy in treatment of peritoneal carcinosis from colorectal background. Few studies have been published on the use of HCIP in peritoneal carcinosis from ovarian background but most of them were non-randomized phase II studies on a small population using different type of drugs and dosage. before this heterogeneity it seems necessary to standardize the utilization modalities of HCIP in peritoneal carcinosis from ovarian background